InMode (INMD)
Builds energy-based systems for aesthetic and medical treatments in clinical practices.
Something off on this page? Send us feedback.
Energy-based aesthetic and medical-treatment systems are sold to physicians and practices through platforms, handpieces, consumables, and warranties. The United States is the largest reported market, while regulatory clearances, physician training, and outsourced manufacturing shape operations.
Energy-based aesthetic and medical-treatment systems are sold to physicians and clinical practices through multi-technology workstations, handpieces, consumables, and extended warranties. IgniteRF, OptimasMAX, EvolveX, EmpowerRF, and Morpheus8 organize radiofrequency, fractional RF, IPL, laser, and related applications.
The United States is the largest reported customer geography, alongside Europe and Asia. Product innovation, physician relationships and training, sales productivity, and market acceptance shape commercial execution.
Devices require ongoing regulatory compliance, including FDA clearances for products, modified products, and expanded indications. Almost all manufacturing is outsourced to a small group of subcontractors, making supplier continuity part of the operating model.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 7, 2026 | Barclays | Reiterate | Rating: —Target: $27 | Target: $19 |
| Feb 11, 2026 | Robert W. Baird | Target | Target: — | Target: $17 |
| Dec 17, 2025 | Canaccord Genuity | Reiterate | Rating: —Target: $16 | Target: $15 |
| Apr 29, 2025 | BTIG | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $501.1M · Total debt $4.5M · Total assets $720.3M · Shareholders' equity $629.1M
- Revenue
- $95.6M
- Operating income
- $12.3M
- Net income
- $17.1M
No dividends on record.
| Institutions | 54.82% | 31.51M ADS | |
|---|---|---|---|
| 204 holders · as of Jun 30, 2026 | |||
| Other | 45.18% | 25.97M ADS | |
| remainder | |||
57.48M ADS as of Sep 7, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Doma Perpetual Capital Management LLCInstitution | 4.75% | 2.73M ADS | as of Jun 30, 2026 |
Acadian Asset Management LLCInstitution | 4.50% | 2.58M ADS | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 4.34% | 2.50M ADS | as of Jun 30, 2026 |
Renaissance Technologies LLCInstitution | 4.16% | 2.39M ADS | as of Jun 30, 2026 |
Menora Mivtachim Holdings Ltd.Institution | 3.55% | 2.04M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- AbbVie
Noninvasive body contouring through CoolSculpting
- Apyx® Medical
Surgical body contouring with plasma and integrated modalities
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| InMode | $14.45 | 0.00% | $833.5M | 11.8 | 10.9 | 2.2 | −0.0% |
| AbbVie | $265.04 | −0.09% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Apyx® Medical | $2.95 | 0.00% | $122.5M | — | — | 2.1 | +22.1% |
| Median | 74.5 | 17.5 | 4.7 | +16.1% |